Intramuscular DNA vaccine provides protection in non-human primate and mouse models of SARS-CoV-2

Intramuscular DNA vaccine provides protection in non-human primate and mouse models of SARS-CoV-2

Nucleic acid vaccine approaches have proven successful in the context of the SARS-CoV-2 pandemic, however challenges with delivery remain. Here we describe PlaCCine, a DNA-based vaccine platform that utilizes a device- and vector-free chemical delivery system. This system includes a DNA plasmid enco...

Full description

Saved in:
Bibliographic Details
Main Authors: Subeena Sood, Ebony N. Gary, Majed Matar, Jessica Kim, Casey E. Hojecki, Bryce Warner, Robert Vendramelli, Thang Truong, Alanna Smith, Jennifer Rice, Jeff Sparks, Michael DeSalvo, John Henderson, Joseph A. Rogers, Ankur Sharma, Laurent Pessaint, Carlo A. Iavarone, Darwyn Kobasa, Jean D. Boyer, Stacy Lindborg, Khursheed Anwer
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Immunology
Subjects:
DNA
vaccine
primate
mice
immunology
plasmid
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1589584/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nucleic acid vaccine approaches have proven successful in the context of the SARS-CoV-2 pandemic, however challenges with delivery remain. Here we describe PlaCCine, a DNA-based vaccine platform that utilizes a device- and vector-free chemical delivery system. This system includes a DNA plasmid encoding the target antigen and generates robust immune responses, offering significant protection against live viral challenges in both non-human primates and mice. We designed spike plasmid immunogens representing early SARS-CoV-2 strains and found that parental spike PlaCCine vaccination induced SARS-CoV-2 specific cellular and humoral responses in non-human primates and supported significant viral control following challenge. To evaluate immunogenicity and protective efficacy against emerging variants, we further advanced the platform to incorporate the SARS-CoV-2 XBB1.5 variant and observed robust, dose-dependent cellular and humoral responses in mice. When mice were immunized and intranasally challenged with 1×105 TCID50 of SARS-CoV-2 XBB1.5 virus, all immunized animals survived the challenge and displayed undetectable lung viral loads. Together these data demonstrate the efficacy of the PlaCCine platform for the delivery of vaccine antigens and support the continued translation of this platform for infectious diseases.
ISSN:1664-3224

Similar Items